CLINICAL_TRIALS
trial_result
· 2019-01-30
Clinical Trial Update: A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer [Phase 1, Phase 2]
Summary
A Phase 1/2 study of BMS-986183 in hepatocellular carcinoma was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-01-30